Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment.

about

Current status of immunotherapy for sarcomas.

P2860

Q49557938-AF88965D-DC0E-4AFC-BD32-A2FF0C233ACF

P2860

Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment.

Item

http://www.wikidata.org/entity/Q38737781

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment.

@en

type

Item

label

Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment.

@en

prefLabel

Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment.

@en

P1476

Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment.

@en

P2093

Elie El Rassy

http://www.w3.org/2001/XMLSchema#string

Fouad Aoun

http://www.w3.org/2001/XMLSchema#string

Joseph Katan

http://www.w3.org/2001/XMLSchema#string

Simone Albisinni

http://www.w3.org/2001/XMLSchema#string

Tarek Assi

http://www.w3.org/2001/XMLSchema#string

P2860

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Development of PD-1/PD-L1 Pathway in Tumor Immune Microenvironment and Treatment for Non-Small Cell Lung Cancer

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

Comprehensive molecular characterization of urothelial bladder carcinoma

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Natural innate and adaptive immunity to cancer

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

P304

451-460

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/IMT-2017-0007

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28357911

http://www.w3.org/2001/XMLSchema#string

Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment.

about

P2860

P2860

Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698